Little patients, losing patience: pediatric cancer drug development

被引：37

作者：

Boklan, Jessica ^{[1
]}

机构：

[1] Phoenix Childrens Hosp, Ctr Canc & Blood Disorders, Phoenix, AZ 85016 USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2006年 / 5卷 / 08期

关键词：

D O I：

10.1158/1535-7163.MCT-06-0179

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1905 / 1908

页数：4

共 18 条

[1]

*ASS TASK FORC CHI, DEC MAK RES PART

[2]

*BIOT IND ORG, HIST PED STUD RUL LE

[3] The price of innovation: new estimates of drug development costs [J].

DiMasi, JA ;

Hansen, RW ;

Grabowski, HG .

JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185

[4]

*FDA, 2006, PED EXCL STAT FEB 28

[5] Regulatory approvals of pediatric oncology drugs: Previous experience and new initiatives [J].

Hirschfeld, S ;

Ho, PTC ;

Smith, M ;

Pazdur, R .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (06) :1066-1073

[6]

ISSA JP, 2005, 47 AM SOC HERM ANN M

[7] Cancer statistics, 2004 [J].

Jemal, A ;

Tiwari, RC ;

Murray, T ;

Ghafoor, A ;

Samuels, A ;

Ward, E ;

Feuer, EJ ;

Thun, MJ .

CA-A CANCER JOURNAL FOR CLINICIANS, 2004, 54 (01) :8-29

[8]

MEADOWS M, 2003, DRUG RES CHILDREN

[9]

MILLER RW, 1995, CANCER, V75, P395, DOI 10.1002/1097-0142(19950101)75:1+<395::AID-CNCR2820751321>3.0.CO

[10]

2-W

← 1 2 →